What’s Ahead for Flexion Therapeutics Incorporated (NASDAQ:FLXN) After More Shorted Shares?

August 24, 2017 - By reb123z

 What’s Ahead for Flexion Therapeutics Incorporated (NASDAQ:FLXN) After More Shorted Shares?

Investors sentiment increased to 2.54 in 2016 Q4. Its up 1.00, from 1.54 in 2016Q3. It increased, as 8 investors sold Flexion Therapeutics Inc shares while 16 reduced holdings. 19 funds opened positions while 42 raised stakes. 21.98 million shares or 21.15% more from 18.14 million shares in 2016Q3 were reported.
State Street holds 391,606 shares. Janney Montgomery Scott Ltd accumulated 10,375 shares. Keybank Association Oh accumulated 10,357 shares or 0% of the stock. Jpmorgan Chase And invested in 125,822 shares or 0% of the stock. 38,996 were reported by Highbridge Cap Management Limited Liability Corp. Alliancebernstein Limited Partnership holds 0% in Flexion Therapeutics Inc (NASDAQ:FLXN) or 26,000 shares. Southport Mngmt Limited Liability Company, Wyoming-based fund reported 25,000 shares. Grt Prns Ltd Company holds 15,432 shares or 0.08% of its portfolio. Quantbot Technologies Lp stated it has 1,218 shares or 0% of all its holdings. Credit Suisse Ag owns 18,229 shares for 0% of their portfolio. Sei Invs Company has 500 shares. Citadel Advsrs Limited Liability Company holds 36,723 shares or 0% of its portfolio. Colorado-based Alps Advsrs has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Bridgeway reported 0.01% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Moreover, Blackrock Advisors Lc has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 13,762 shares.

Since February 28, 2017, it had 3 buys, and 4 insider sales for $770,078 activity. Another trade for 33,434 shares valued at $667,679 was made by DRISCOLL FREDERICK W on Tuesday, February 28. 5,000 Flexion Therapeutics Inc (NASDAQ:FLXN) shares with value of $85,048 were bought by COLELLA SAMUEL D. Bodick Neil sold $129,448 worth of stock. Stejbach Mark also bought $26,888 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) shares.

The stock of Flexion Therapeutics Incorporated (NASDAQ:FLXN) registered an increase of 5.49% in short interest. FLXN’s total short interest was 5.08M shares in August as published by FINRA. Its up 5.49% from 4.81 million shares, reported previously. With 488,300 shares average volume, it will take short sellers 10 days to cover their FLXN’s short positions. The short interest to Flexion Therapeutics Incorporated’s float is 20.87%.

About 199,522 shares traded. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 82.02% since August 24, 2016 and is uptrending. It has outperformed by 65.32% the S&P500.

Flexion Therapeutics, Inc. is a United States specialty pharmaceutical company. The company has market cap of $789.03 million. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis , a type of degenerative arthritis. It currently has negative earnings. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage

Among 8 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 11 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Outperform”. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) has “Buy” rating given on Friday, July 7 by RBC Capital Markets. The rating was initiated by Cantor Fitzgerald with “Buy” on Wednesday, November 4. On Tuesday, May 3 the stock rating was reinitiated by Wells Fargo with “Outperform”. BMO Capital Markets maintained it with “Buy” rating and $3500 target in Monday, June 26 report. Cantor Fitzgerald maintained the shares of FLXN in report on Monday, June 12 with “Buy” rating. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Buy” rating by Needham on Wednesday, September 9. The stock has “Buy” rating by Lake Street on Thursday, July 21.

More notable recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Seekingalpha.com which released: “Flexion Therapeutics Inc.: Teeing up to disrupt the osteoarthritis market” on August 24, 2017, also Fool.com with their article: “Why Flexion Therapeutics Rallied 18% in June” published on July 07, 2017, Fool.com published: “Why Flexion Therapeutics Shares Shot 12.8% Higher in July” on August 07, 2017. More interesting news about Flexion Therapeutics Inc (NASDAQ:FLXN) were released by: Seekingalpha.com and their article: “Flexion Therapeutics: Novel Knee Osteoarthritis Therapy With Upcoming Catalyst” published on February 24, 2017 as well as Fool.com‘s news article titled: “Here’s Why Flexion Therapeutics Inc. Skyrocketed Today” with publication date: March 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.